<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186494</url>
  </required_header>
  <id_info>
    <org_study_id>RS19-023</org_study_id>
    <nct_id>NCT04186494</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea</brief_title>
  <official_title>The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's University Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's University Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an explorative, proof-of-concept study exploring the potential therapeutic role of a
      Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on
      metabolic parameters, blood pressure, endothelial function, coronary artery calcification,
      vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to
      severe obstructive sleep apnea
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in insulin resistance defined by HOMA-IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>6 months</time_frame>
    <description>Change in body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>6 months</time_frame>
    <description>Change in glucose tolerance measured by oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSA Severity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in apnea/hypopnea index as per polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Change in 24-hour blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>6 months</time_frame>
    <description>Change in microvascular endothelial function measured by EndoPat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcification</measure>
    <time_frame>6 months</time_frame>
    <description>Change in coronary artery calcification score determined by Coronary artery CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Change in vascular inflammation determined via FDG-PET scan</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure (CPAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard CPAP Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide-based weight loss regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination CPAP/Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of both interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml</intervention_name>
    <description>GLP-1 analogue treatment in combination with advice on diet and physical exercise</description>
    <arm_group_label>Liraglutide-based weight loss regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure treatment</intervention_name>
    <description>Gold standard treatment for obstructive sleep apnea</description>
    <arm_group_label>Continuous positive airway pressure (CPAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Liraglutide and CPAP</intervention_name>
    <description>Combination of both treatments</description>
    <arm_group_label>Combination CPAP/Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed moderate-severe OSA (by standard PSG)

          -  Body mass index between 30 - 40

          -  Age 18 - 60 years

          -  Able to provide written, informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Requirement for supplemental oxygen

          -  Previous diagnosis of OSA or previous CPAP treatment

          -  Diagnosis of Diabetes

          -  Previous treatment with GLP-1 analogue

          -  Previous surgical treatment for obesity

          -  Active treatment for malignancy or severe psychiatric disorder

          -  Acute coronary syndrome or stroke within 3 months prior to study

          -  History of decompensated heart failure

          -  Professional drivers or drivers with a history of road-traffic accident due to
             sleepiness

          -  Severe excessive daytime sleepiness defined as Epworth sleepiness scale &gt;15
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke Ryan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's University Hospital, University College Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silke Ryan, PhD, MD</last_name>
    <phone>+35312213702</phone>
    <email>silke.ryan@ucd.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 4</state>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Ryan</last_name>
      <phone>+35312213702</phone>
      <email>silke.ryan@ucd.ie</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's University Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr Silke Ryan</investigator_full_name>
    <investigator_title>Associate Professor, Consultant in Respiratory and Sleep Medicine</investigator_title>
  </responsible_party>
  <keyword>Liraglutide</keyword>
  <keyword>Continuous positive airway pressure</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Vascular inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

